ClinicalTrials.gg

Program

MK-6916

A development code.

Its studies are mostly in Renal Insufficiency, led by Merck.

Furthest: phase 2, since Oct 2, 20264 company-led studies, 3 open or runningNext primary completion: Feb 9, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck43 open or runningphase 2since Oct 2, 2026Feb 5, 2025Feb 9, 2027phase 1 · NCT07862621

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2025First study: phase 1 study in HealthyFirst studyNCT06818968 · 37 enrolled · United States
  2. Oct 2, 2026Phase 1 study in HealthyNCT07862621 · 18 planned
  3. Oct 2, 2026Phase 2 study in AgnosiaPhase 2 reachedNCT07862595 · 380 planned · United States
  4. Nov 2, 2026Phase 1 study in Renal InsufficiencyNCT07922174 · 32 planned

Ahead

  1. Feb 9, 2027Primary completion: phase 1 study in HealthyNCT07862621
  2. Jun 10, 2027Primary completion: phase 2 study in AgnosiaNCT07862595
  3. Aug 6, 2027Primary completion: phase 1 study in Renal InsufficiencyNCT07922174

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07922174Renal Insufficiency1Not yet recruitingAug 6, 202732
NCT07862621Healthy1Not yet recruitingFeb 9, 202718
NCT07862595Agnosia · United States2Not yet recruitingJun 10, 2027380
NCT06818968Healthy · United States1CompletedAug 8, 202537

How it is read

Names in the registry

  • “MK-6916”, 4 entries

Codes read as this program: MK6916.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.